Safety Study of TH9507 in Subjects With Stable, Type 2 Diabetes
Status:
Completed
Trial end date:
2002-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to determine whether TH9507, a stabilized analogue of growth
hormone-releasing factor (GRF), would have an effect on insulin sensitivity or control of
diabetes in patients with type 2 diabetes.